ERBB2 as a Prognostic Biomarker in Prostate Cancer: Integration of Single-Cell Transcriptomics, Deep Learning, and Immunohistochemical Validation | Synapse
March 3, 2026
ERBB2 as a Prognostic Biomarker in Prostate Cancer: Integration of Single-Cell Transcriptomics, Deep Learning, and Immunohistochemical Validation
Key Points
ERBB2 expression correlates with prostate cancer outcomes, indicating its role as a potential prognostic biomarker.
Key evidence includes a significant association between high ERBB2 levels and poor survival rates in prostate cancer patients.
The approach utilized single-cell transcriptomics combined with deep learning techniques for data analysis and validation.
This work supports the need for external validation of ERBB2's prognostic value in larger, diverse patient populations.